Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.36USD
18 Sep 2019
Change (% chg)

-- (--)
Prev Close
$5.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,379
52-wk High
$7.50
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Merrimack - JFL Capital Management Has Launched "Unnecessary" Proxy Contest To Replace Entire Board, Effectively Seeking To Acquire Co
Monday, 26 Aug 2019 

Aug 26 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS.MERRIMACK - JFL CAPITAL MANAGEMENT HAS LAUNCHED "UNNECESSARY" PROXY CONTEST TO REPLACE ENTIRE BOARD - EFFECTIVELY SEEKING TO ACQUIRE CO.MERRIMACK - JFL'S RESPONSE TO ATTEMPTS AT CONSTRUCTIVE SETTLEMENT TO DATE HAS BEEN THEY WERE "UNINTERESTED" IN ANY OUTCOME BESIDES CONTROL OF CO.  Full Article

JFL Capital Issues Letter To Fellow Merrimack Stockholders
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - Merrimack Pharmaceuticals Inc ::JFL CAPITAL ISSUES LETTER TO FELLOW MERRIMACK STOCKHOLDERS.JFL CAPITAL MANAGEMENT - HAS OWNERSHIP OF ABOUT 18.7% OF MERRIMACK PHARMACEUTICALS'S OUTSTANDING SHARES.JFL CAPITAL - BELIEVE OVERHAUL IN MERRIMACK PHARMACEUTICALS BOARDROOM WARRANTED.JFL CAPITAL - NOMINATED JASON ARYEH, ARON ENGLISH, JOSEPH LAWLER, AND KENNETH LIN FOR ELECTION TO MERRIMACK'S BOARD.JFL CAPITAL - FUTURE TRANSACTIONS WORTH CONSIDERING FOR MERRIMACK IS RUNNING THOROUGH SALES PROCESS FOR POTENTIAL MILESTONE PAYMENTS FROM IPSEN.JFL CAPITAL - FUTURE TRANSACTIONS WORTH CONSIDERING FOR MERRIMACK INCLUDE A POSSIBLE RESTRUCTURING.  Full Article

Merrimack Pharmaceuticals On July 15 Dismissed PWC As Co's Independent Registered Public Accounting Firm
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC - ON JULY 15, CO DISMISSED PWC AS COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.MERRIMACK - PWC'S REPORTS FOR FY ENDED 2017, 2018 HAD PARAGRAPH INDICATING THAT CO WILL NEED ADDITIONAL FINANCING TO FUND FUTURE OPERATIONS.  Full Article

Merrimack Pharmaceuticals To Incur Charges In Connection With Headcount Reduction Of About $3.3 Mln-$3.6 Mln
Monday, 1 Jul 2019 

July 1 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS - TO INCUR CHARGES FOR ONE-TIME TERMINATION BENEFITS IN CONNECTION WITH HEADCOUNT REDUCTION OF ABOUT $3.3 MILLION-$3.6 MILLION.MERRIMACK PHARMACEUTICALS - REDUCTION IN HEADCOUNT SUBSTANTIALLY COMPLETED BY JUNE 28, 2019 AND IS EXPECTED TO BE FULLY COMPLETED IN JULY 2019.  Full Article

Merrimack Pharmaceuticals Says Richard Peters President, CEO And Director, Resigned From Each Position As Of June 28, 2019
Monday, 1 Jul 2019 

July 1 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS INC - ON JUNE 25, RICHARD PETERS, PRESIDENT, CEO AND DIRECTOR, RESIGNED FROM EACH SUCH POSITION AS OF JUNE 28, 2019.MERRIMACK PHARMACEUTICALS - ON JUNE 25, JEAN FRANCHI, CFO AND TREASURER, RESIGNED FROM EACH SUCH POSITION AS OF JUNE 28, 2019..  Full Article

Merrimack Pharmaceuticals Announces Plan To Reduce Size Of Board
Thursday, 30 May 2019 

May 30 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF STRATEGIC REVIEW, PRESERVATION OF IPSEN MILESTONES AND SPECIAL CASH DIVIDEND.MERRIMACK PHARMACEUTICALS - BOARD IMPLEMENTING SERIES OF MEASURES DESIGNED TO EXTEND CO'S CASH RUNWAY INTO 2027.MERRIMACK PHARMACEUTICALS INC - BEST OUTCOME AVAILABLE FOR SHAREHOLDERS IS TO RESTRUCTURE CO SUCH THAT CASH RUNWAY COULD EXTEND INTO 2027.MERRIMACK PHARMACEUTICALS- WORKFORCE REDUCTION, AFFECTING EXECUTIVE LEADERSHIP TEAM, REMAINING EMPLOYEES, TO BE SUBSTANTIALLY COMPLETED BY JUNE 28.MERRIMACK PHARMACEUTICALS - PLAN TO REDUCE SIZE OF COMPANY'S BOARD.MERRIMACK PHARMACEUTICALS- AUTHORIZATION OF NEAR-TERM SPECIAL CASH DIVIDEND OF BETWEEN $16.9 MILLION AND $18.9 MILLION IF ASSET SALE TO 14NER ONCOLOGY CLOSES.MERRIMACK - AUTHORIZATION OF NEAR-TERM SPECIAL CASH DIVIDEND BETWEEN $13.4 MILLION - $15.4 MILLION IF ASSET SALE TO 14NER ONCOLOGY DOES NOT SUCCESSFULLY CLOSE.  Full Article

Merrimack Pharmaceuticals Discontinues Development Of MM-310
Thursday, 4 Apr 2019 

April 4 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK DISCONTINUES DEVELOPMENT OF MM-310.MERRIMACK PHARMACEUTICALS INC - EXPECTS TO REDUCE WORKFORCE.MERRIMACK PHARMACEUTICALS INC - CONTINUES TO PRUDENTLY ADVANCE PROGRAMS WHILE COMPLETING ASSESSMENT OF ITS STRATEGIC ALTERNATIVES.MERRIMACK PHARMACEUTICALS INC - CONCLUDED THAT STUDY WOULD NOT BE ABLE TO REACH AN OPTIMAL THERAPEUTIC INDEX FOR MM-310.MERRIMACK PHARMACEUTICALS INC - NARROWED SCOPE OF PIPELINE TO MM-401 AND MM-201; INITIATING STEPS TO CLOSE OUT REMAINING CLINICAL ACTIVITIES.MERRIMACK PHARMACEUTICALS INC - SAFETY UPDATE SHOWS PHASE 1 STUDY UNABLE TO REACH OPTIMAL THERAPEUTIC INDEX FOR MM-310.MERRIMACK - PHASE 1 STUDY UNABLE TO REACH OPTIMAL THERAPEUTIC INDEX FOR MM-310 DUE TO CONTINUED OBSERVATION OF CUMULATIVE PERIPHERAL NEUROPATHY.  Full Article

JFL Partners Nominates 4 People For Election To Merrimack Pharmaceuticals' Board
Thursday, 14 Mar 2019 

March 14 (Reuters) - Merrimack Pharmaceuticals Inc ::JFL PARTNERS SAYS ON MARCH 13, DELIVERED LETTER TO MERRIMACK PHARMACEUTICALS - SEC FILING.JFL PARTNERS SAYS NOMINATING JASON ARYEH, ARON ENGLISH, JOSEPH LAWLER AND KENNETH LIN, FOR ELECTION TO MERRIMACK PHARMACEUTICALS' BOARD.  Full Article

Merrimack Reports Q4 Loss Per Share $0.97
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.97.MERRIMACK PHARMACEUTICALS - BELIEVES CASH, CASH EQUIVALENTS, OTHERS OF $71.3 MILLION AS OF DEC 31, 2018 TO FUND ITS OPERATIONS INTO AT LEAST H2 2022.  Full Article

Merrimack Pharmaceuticals - Expects to have about 27 employees after corporate restructuring - SEC filing
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Merrimack Pharmaceuticals Inc ::MERRIMACK PHARMACEUTICALS - EXPECTS TO HAVE ABOUT 27 EMPLOYEES AFTER CORPORATE RESTRUCTURING - SEC FILING.MERRIMACK PHARMACEUTICALS - TO INCUR EXPENSES RELATED TO RESTRUCTURING OF ABOUT $1.5 MILLION TO $1.8 MILLION FOR EMPLOYEE SEVERANCE, BENEFITS & RELATED COSTS.  Full Article